Century Therapeutics Inc share price logo

Century Therapeutics Inc

NASDAQ: IPSC

Small Cap

$2.28

-0.01

(-0.44%)

as on

Century Therapeutics Inc Stock Performance

as on May 14, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $2.23
    $2.33
    downward going graph

    2.19%

    Downside

    2.19%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.44
    $3.04
    downward going graph

    80.92%

    Downside

    33.33%

    Upside

    downward going graph

Century Therapeutics Inc share price movements today

Previous Close
$2.29
Open
$2.23
Volume
1.1M
Day's Low - High
$2.23 - $2.33
52 Week Low - High
$0.44 - $3.04

Century Therapeutics Inc Historical Returns

1 Month Return
-3.38 %
3 Month Return
+ 30.86 %
1 Year Return
+ 368.21 %
3 Year Return
-30.18 %
5 Year Return
0 %

Century Therapeutics Inc Stock Fundamentals & Key Indicators

Check Century Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$413.0M

EPS (TTM)

-0.625

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-1.9M

Revenue (TTM)

109.2M

Profit Margin

-8.78%

Return On Equity TTM

-5.98%

Century Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Century Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$413.0MNANA-8.78%
BUY$38.0B115.2%71.3912.55%
NA$32.7BNA71.448.94%
BUY$110.4B106.5%25.8435.51%
BUY$74.7B40.03%17.3929.65%

Stock Returns calculator for Century Therapeutics Inc Stock including INR - Dollar returns

The Century Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Century Therapeutics Inc investment value today

Current value as on today

₹5,22,221

Returns

₹4,22,221

(+422.22%)

Returns from Century Therapeutics Inc Stock

₹3,65,306 (+365.31%)

Dollar Impact

₹56,915 (+56.91%)

Analyst Recommendation on Century Therapeutics Inc Stock

Based on 13 analysts

BUY

84.62%

Buy

15.38%

Hold

0.00%

Sell

Based on 13 analysts, 84.62% of analysts recommend a 'BUY' rating for Century Therapeutics Inc. Average target price of $3.67

Century Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Century Therapeutics Inc.

What analysts predicted

37.87%UPSIDE

Target Price

$3.67

Current Price

$2.28

Analyzed by

13 Analysts

Target

$3.67

Century Therapeutics Inc target price $3.67, a slight upside of 37.87% compared to current price of $2.28. According to 13 analysts rating.

Indian Investors' Interest in Century Therapeutics Inc Stock

Search interest for Century Therapeutics Inc Stock has decreased by -44% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-44% versus previous 30 day period

Century Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
0
0
0
0
0
4
109
-
-
-
Gross Profit
-22
-22
0
0
0
4
109
-3
-3
-3
Operating Income
-35
-43
-31
-34
-34
-37
74
-34
-29
-25
EBITDA
-28
-27
-28
-27
-27
-30
77
-29
-31
-18
Interest Expense
-
1
-
-
-
-
-
-
-
-
Depreciation
3
3
3
3
3
3
3
3
3
3
Income Before Tax
-32
-40
-28
-31
-31
-34
76
-32
-34
-19
Income Tax Expense
0
0
0
0
0
1
-
-
-
0
Net Income
-32
-39
-28
-31
-31
-36
76
-32
-34
-19
Net Profit Margin
-22108.11%
-14700.75%
-3282.11%
-4047.60%
-3947.66%
-864.44%
70.13%
0.00%
0.00%
0.00%

Century Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
1
5
2
6
109
Gross Profit
0
-1
-4
5
2
6
96
Operating Income
-20
-49
-94
-133
-146
-138
-15
EBITDA
-244
-51
-89
-121
-121
-111
-1
Interest Expense
-
0
1
1
0
-
-
Depreciation
0
1
3
8
12
13
13
Income Before Tax
-244
-53
-95
-130
-134
-124
-9
Income Tax Expense
1
1
0
0
1
1
0
Net Income
-244
-53
-95
-130
-136
-126
-9
Net Profit Margin
0.00%
0.00%
-9057.09%
-2518.41%
-6115.12%
-1920.87%
-8.78%

Century Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-39
-28
-31
-31
-36
76
-32
-34
-19
Operating Cash Flow
-26
-30
-27
-28
-24
-34
-27
-25
-16
Investing Cash Flow
18
11
-33
39
30
27
32
24
22
Financing Cash Flow
0
18
56
0
0
0
-
-
0
Change in Cash
-7
0
-4
11
5
-6
4
0
6

Century Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-
-244
-53
-95
-130
-136
-126
-9
Operating Cash Flow
-
-16
-41
-89
14
-88
-110
-103
Investing Cash Flow
-
-19
-22
-298
-13
61
47
107
Financing Cash Flow
98
74
47
417
27
-9
74
0
Change in Cash
-
38
-16
30
28
-36
11
3

Global Institutional Holdings in Century Therapeutics Inc

Funds
Holdings
Adage Capital Partners Gp LLC
1.02%
Spruce Street Capital LP
0.79%
Acadian Asset Management LLC
0.4%
Point72 Asset Management, L.P.
3.31%
Vanguard Group Inc
1.17%

Insights on Century Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, IPSC stock has moved up by 384.9%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, IPSC has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -34.42M → -19.17M (in $), with an average increase of 79.5% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 771.0K → 109.16M (in $), with an average increase of 59.9% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 32.2% return, outperforming this stock by 62.4%

About Century Therapeutics Inc

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
OrganisationCentury Therapeutics Inc
Headquarters25 North 38th Street, Philadelphia, PA, United States, 19104
IndustryBiotechnology
CEODr. Brent Pfeiffenberger M.B.A., Pharm.D.
E-voting on sharesClick here to vote

Key Management of Century Therapeutics Inc

Name

Title

Ms. Megan Bilson

Chief People Officer

Michael Naso Ph.D.

Senior VP of Cell Engineering

Ms. Elizabeth Devlin

VP & Head of Development

Dr. Brent Pfeiffenberger M.B.A., Pharm.D.

President, CEO & Chairman

Dr. Gregory Russotti Ph.D.

Chief Technology & Manufacturing Officer

Dr. Chad A. Cowan Ph.D.

Chief Scientific Officer

Mr. Douglas Carr CPA

Senior VP of Finance & Operations, Principal Financial Officer and Secretary

Krista Kauppinen J.D., Ph.D.

VP, General Counsel & Head of Intellectual Property

FAQs

What is Century Therapeutics Inc share price today?

Century Therapeutics Inc share price today is $2.28 as on at the close of the market. Century Therapeutics Inc share today touched a day high of $2.33 and a low of $2.23.

What is the 52 week high and 52 week low for Century Therapeutics Inc share?

Century Therapeutics Inc share touched a 52 week high of $3.04 on and a 52 week low of $0.44 on . Century Therapeutics Inc stock price today i.e. is closed at $2.28,which is 25.00% down from its 52 week high and 424.14% up from its 52 week low.

What is Century Therapeutics Inc's market capitalisation today?

Century Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Century Therapeutics Inc Stock (IPSC) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Century Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Century Therapeutics Inc Shares that will get you 0.6579 shares as per Century Therapeutics Inc share price of $2.28 per share as on May 14, 2026 at 8:46 am IST.

What is the minimum amount required to buy Century Therapeutics Inc Stock (IPSC) from India?

Indian investors can start investing in Century Therapeutics Inc (IPSC) shares with as little as ₹95.705 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹957.05 in Century Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Century Therapeutics Inc share’s latest price of $2.28 as on May 14, 2026 at 8:46 am IST, you will get 4.3860 shares of Century Therapeutics Inc. Learn more about fractional shares .